Natus Medical Incorporated (NASDAQ:NTUS) has been assigned an average broker rating score of 3.00 (Hold) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating.
Zacks has also assigned Natus Medical an industry rank of 63 out of 255 based on the ratings given to its competitors.
A number of research firms have weighed in on NTUS. Zacks Investment Research lowered shares of Natus Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, February 12th. ValuEngine raised shares of Natus Medical from a “sell” rating to a “hold” rating in a research report on Friday, February 21st.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NTUS. Altshuler Shaham Ltd bought a new position in Natus Medical during the 4th quarter valued at $33,000. Advisory Services Network LLC purchased a new stake in shares of Natus Medical in the fourth quarter valued at about $35,000. LS Investment Advisors LLC bought a new position in shares of Natus Medical during the fourth quarter valued at about $37,000. Royce & Associates LP bought a new position in shares of Natus Medical during the fourth quarter valued at about $42,000. Finally, First Mercantile Trust Co. bought a new position in shares of Natus Medical during the fourth quarter valued at about $49,000. 90.92% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:NTUS traded down $0.58 during trading on Friday, reaching $28.20. 113,300 shares of the stock were exchanged, compared to its average volume of 137,808. Natus Medical has a 1-year low of $22.25 and a 1-year high of $34.89. The stock has a fifty day moving average of $32.12 and a two-hundred day moving average of $31.60. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.89 and a quick ratio of 1.39. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -104.44 and a beta of 0.74.
Natus Medical (NASDAQ:NTUS) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.46 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.01). The business had revenue of $131.76 million during the quarter, compared to analyst estimates of $130.00 million. Natus Medical had a negative net margin of 1.79% and a positive return on equity of 10.54%. The business’s revenue for the quarter was down 6.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.43 EPS. Sell-side analysts forecast that Natus Medical will post 1.5 EPS for the current year.
Natus Medical Company Profile
Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Recommended Story: How prevalent are 12b-1 fees?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.